Genentech’s CEO on Big Pharma’s Issues Arthur Levinson tackles drug pricing, patent disputes, consumer marketing, and stem-cell research

FDA’s McClellan Calls for More Sharing of Drug R&D Costs The U.S. is bearing a disproportionate share of drug research

FDA’s McClellan Calls for More Sharing of Drug R&D Costs The U.S. is bearing a disproportionate share of drug research

Drug Development, Genentech Style “Its promising colon cancer fighter Avastin is a prime example of how the biotech ‘keeps following

BIOTECH THAWS OUT: “Small drug discovery firms are capitalizing on the positive momentum that’s returned to the market for biotechnology

Suit targets 13 generic drug makers “Jumping into the escalating legal battle against pharmaceutical manufacturers, Attorney General Thomas F. Reilly

Judge Allows Antitrust Case Against Seed Producers “A federal judge on Friday let proceed an antitrust case that accused the

Definitions Impede Stem-Cell Work The medical promise of embryonic stem-cell research has been plagued by ethical controversy. Now, an apparent

Bioterror Brain Drain “Infectious-disease specialists are following the big bucks to Washington’s new multibillion-dollar program on bioterrorism research�but at what

A dose of reality “The FDA yesterday opened two days of hearings on the subject of consumer advertising, for the